Group 1 - Monteverde & Associates PC is investigating iCAD, Inc. in relation to its proposed merger with RadNet, Inc., where iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock held at the closing of the merger [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and is a national class action securities firm with experience in trial and appellate courts, including the U.S. Supreme Court [2][3] Group 2 - The firm encourages shareholders with concerns regarding iCAD, Inc. to visit their website or contact them for additional information free of charge [3] - Monteverde & Associates PC emphasizes that no company, director, or officer is above the law, reinforcing their commitment to shareholder rights [3] - The firm provides a platform for potential clients to inquire about their litigation history and success in recovering funds for shareholders [4]

Core Viewpoint - RadNet, Inc. has announced a definitive merger agreement to acquire iCAD, Inc. in an all-stock transaction valued at approximately $103 million, representing a significant premium for iCAD stockholders [1][2]. Group 1: Merger Details - iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger, equating to about $3.61 per share on a fully diluted basis [2]. - The transaction is expected to close in the second or third quarter of 2025, pending approval from iCAD stockholders and other customary closing conditions [3]. Group 2: Strategic Rationale - The merger aims to enhance patient diagnosis and outcomes in breast cancer detection through the combined capabilities of iCAD's ProFound Breast Health Suite and RadNet's DeepHealth AI-powered solutions [3]. - The acquisition will expand RadNet's existing network, which includes over 1,500 healthcare provider locations and facilitates over 8 million annual mammograms across 50 countries [3][5]. Group 3: Leadership Comments - Dr. Howard Berger, CEO of RadNet, emphasized the potential to improve global breast cancer diagnosis and outcomes through this merger [3]. - Dana Brown, CEO of iCAD, highlighted the opportunity to redefine disease detection and treatment, aiming to enhance access to advanced tools and improve patient care [3]. Group 4: Future Plans - Following the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio, which is expected to accelerate growth and leadership in cancer screening and artificial intelligence [5]. - RadNet plans to host an investor conference call to discuss the transaction details, indicating a commitment to transparency and stakeholder engagement [4][5].

Core Viewpoint - iCAD, Inc. has appointed Mark Koeniguer as Chief Commercial Officer to drive global growth and enhance its AI-powered breast health solutions [1][2]. Company Overview - iCAD, Inc. is a leader in providing AI-powered solutions for early cancer detection, particularly in breast health, with its ProFound Breast Health Suite used in over 50 countries [5]. - The company has estimated that it has read more than 40 million mammograms in the last five years, with nearly 30% being tomosynthesis [5]. Leadership Appointment - Mark Koeniguer brings over 30 years of experience in MedTech, AI, and digital health, previously serving as CEO of ScreenPoint Medical, where he increased annual recurring revenue by 400% [3]. - In his role as CCO, Koeniguer will oversee commercial sales teams, partnerships, operations, and customer success, focusing on revenue growth in North America and globally [2][4]. Strategic Goals - The appointment of Koeniguer is aimed at better engaging with global health providers and enhancing clinical workflows and patient experiences [4]. - The leadership believes Koeniguer's expertise in radiological health and AI solutions will be instrumental in advancing iCAD's mission to transform breast cancer detection [4].

Financial Performance - The Company incurred a net loss of approximately $5.6 million in 2024, with an accumulated deficit of approximately $277 million as of December 31, 2024[146]. - The Company's quarterly and annual operating and financial results are likely to fluctuate significantly due to various external factors[147]. - The Company expects its cash and cash equivalents of $17.2 million as of December 31, 2024, to fund operations for at least the next twelve months[148]. - The company reported goodwill of $8.4 million as of December 31, 2024, which is subject to impairment assessments that could adversely affect future earnings[172]. - Approximately 14% of the Company's revenue for the fiscal year ended 2024 was derived from customers outside of the U.S., primarily in Europe[182]. - The company sold 1,057,814 shares of its common stock at a weighted average price of $2.18 per share, resulting in cash proceeds of $2.0 million for the year ended December 31, 2023[243]. Revenue and Market Risks - The Company has paused U.S. sales of its ProFound AI® Risk product pending FDA regulatory clearance, which may impact future revenue[152]. - The markets for the Company's products may not develop as expected, leading to barriers in achieving broad market acceptance[156]. - The Company relies on a limited number of customers for a significant portion of its total revenue, making it vulnerable to the loss of key clients[146]. - The company's revenue from OEM partners accounted for 26% of total revenue in 2024, with GE Healthcare contributing 17%[170]. - The market for full field digital mammography systems and related products is crucial for the company's future growth, but may not develop as anticipated due to economic conditions and reimbursement issues[169]. - The healthcare industry consolidation could reduce the Company's potential customer base and demand for its systems, impacting revenue generation[188]. Operational and Compliance Risks - The Company faces legal, business, and operational risks associated with the use of AI and machine learning technologies in its offerings[146]. - The Company may be exposed to significant product liability claims, which could harm its reputation and financial condition[160]. - The Company must comply with Nasdaq's continued listing requirements, including maintaining a minimum closing bid price of $1.00 per share[196]. - The healthcare industry is subject to extensive regulation, and non-compliance could result in significant costs, including fines and exclusion from government healthcare programs[205]. - The Company’s CAD systems are classified as medical devices and are subject to extensive FDA regulation, which includes manufacturing operations and product labeling[214]. - Regulatory changes or challenges could adversely affect the Company’s ability to commercialize existing and future products, impacting revenue generation[212]. - The Company may face substantial costs related to compliance with evolving privacy and data protection laws, including HIPAA[226]. - The Company’s operations are subject to audits and investigations from government agencies, which could disrupt business and lead to significant defense costs[209]. - The Company may incur substantial expenses if claims arise regarding the wrongful use or disclosure of confidential information by its employees[187]. - Compliance with healthcare fraud and abuse laws could restrict the Company’s sales and marketing practices, leading to potential legal and financial repercussions[211]. Strategic and Developmental Challenges - The Company is transitioning to a software as a service (SaaS) model, which may impact revenue recognition and cash flow[141]. - The Company is transitioning to a subscription licensing model, which may lead to unpredictable revenue due to limited operating history with this model[171]. - The Company is developing a new product in collaboration with Solis to detect BAC using mammography, but regulatory approval and market acceptance are uncertain[164]. - The Company’s ability to adapt to evolving technologies is critical, as failure to do so may render its products obsolete and negatively impact business[176]. - Clinical trials are expensive and lengthy, with uncertain outcomes that could delay regulatory approvals and revenue generation[189]. - Strategic transactions, such as acquisitions or joint ventures, could disrupt operations and may not yield the anticipated benefits[220]. Financial and Market Conditions - The Company may need to seek additional capital sooner than planned to fund product development and commercialization[149]. - The Company may experience fluctuations in its effective tax rate due to various factors, including changes in geographic earnings mix and tax law changes[173]. - The Company is exposed to competitive pressures from larger firms with greater resources, which could adversely affect its market position[178]. - Changes in credit ratings could lead to increased borrowing costs and limit financing options, potentially affecting the Company's operational flexibility[253]. - Unfavorable global economic conditions, including geopolitical events and inflationary pressures, could weaken demand for the Company's products and impact capital raising efforts[254]. - The Trump administration's proposed tariffs on imports from various countries could significantly affect the U.S. healthcare industry, with potential downstream impacts on the Company[255]. Cybersecurity and Data Protection - The Company faces risks related to cybersecurity incidents that could compromise customer data and result in significant liabilities[247]. - The Company may face significant capital expenditures to protect against security breaches and hackers due to vulnerabilities in its infrastructure and systems[180]. - The European Union's General Data Protection Regulation (GDPR) imposes penalties of up to 4% of worldwide revenue for non-compliance[234]. - The EU AI Act, published in 2024, may impose fines of up to 7% of worldwide annual turnover for breaches related to AI regulations[232]. - The Company is subject to complex regulations regarding AI and machine learning, which may require operational changes and increase costs[232]. Management and Governance - The Company underwent management changes, including the Chief Executive Officer and Chief Financial Officer, during the year ended December 31, 2023[192]. - The Company is classified as a "smaller reporting company," which may make its stock less attractive to investors due to reduced disclosure requirements[244]. - Future issuances of common stock may cause significant dilution of existing shareholders' equity interests[242]. - The Company has the ability to issue up to 1,000,000 shares of preferred stock, which could affect existing stockholders' rights[237]. - The Company's stock price has experienced volatility, which may impair its ability to finance strategic transactions[240]. - The Company is required to assess the effectiveness of its internal controls over financial reporting as per Section 404 of the Sarbanes-Oxley Act, dedicating significant resources for compliance for the year ended December 31, 2024[252].

iCAD, Inc. (NASDAQ:ICAD) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Rosalyn Christian - IR Dana Brown - President, CEO and Chairman Eric Lonnqvist - CFO Conference Call Participants Marie Thibault - BTIG Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Gene Mannheimer - Freedom Capital Markets Operator Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 27, 2025 ________________________ iCAD, INC. (Exact Name of Registrant as Specified in Its Charter) ________________________ 98 Spit Brook Road, Suite 100, Nashua, New Hampshire 03062 (Address of Principal Executive Offices) (Zip Code) (603) 882-5200 (Registrant's ...

Dana Brown, President and CEO of iCAD commented, "Our fourth-quarter results reflect strong momentum in our transition to a SaaS-based model, evidenced by growth of 11% in ARR year-over-year and the signing of 19 cloud deals, a sequential improvement from 13 deals signed in the third quarter of 2024. The growth in customer adoption of ProFound Cloud demonstrates the growing market demand for scalable, AI-powered breast health solutions. Our global expansion efforts continue to gain traction, with new distri ...

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.co ...

Core Insights - iCAD, Inc. and RamSoft have formed a strategic partnership to integrate iCAD's ProFound AI Breast Health Suite into RamSoft's RIS/PACS platform, enhancing breast cancer detection capabilities across North America [1][2][3] Company Overview - iCAD, Inc. is a leader in AI-powered cancer detection solutions, with its ProFound Breast Health Suite designed to improve early detection of breast cancer and enhance patient outcomes [7] - RamSoft provides cloud-based RIS/PACS solutions, utilized by over 750 sites globally, focusing on improving radiology workflows and diagnostic accuracy [5] Partnership Details - The collaboration aims to streamline workflows in imaging centers by integrating ProFound AI into RamSoft's existing platforms, starting with Mammolink, a provider of 3D mammography services [2][3] - The ProFound AI Breast Health Suite addresses the challenge of undetected breast cancers, which range from 20% to 40% in traditional screenings, by offering high sensitivity analysis of mammograms [2] Technology and Features - The PowerServer platform, which will host the ProFound AI integration, is FDA 510(k) cleared and IHE compliant, ensuring high standards of quality and regulatory compliance [3] - Features of the PowerServer include customizable layouts, MG CAD Markers support, and digital breast tomosynthesis (DBT) capabilities, all aimed at enhancing diagnostic efficiency [3] Industry Context - The increasing adoption of AI in healthcare is driven by the need for improved diagnostic accuracy and operational efficiency, particularly in breast cancer screening [2]

NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-p ...